Thryv Therapeutics
QC - Montreal
BiotechnologyFocus: LQT Syndrome Treatment
Thryv Therapeutics is a life sciences company focused on LQT Syndrome Treatment.
Cardiovascular
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Pati
Long QT Syndrome Type 3Clinical Trials (1)
NCT07075445Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3
N/ATHRV-1268
Heart FailureClinical Trials (1)
NCT07186946Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants
Phase 1THRV-1268
Atrial FibrillationClinical Trials (1)
NCT06507839Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268
Phase 1LQT-1213
Long QT SyndromeClinical Trials (1)
NCT05759962Phase 1 Study of LQT-1213 in Healthy Adults
Phase 1LQT-1213
Long QT SyndromeClinical Trials (1)
NCT05906732Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
Phase 1/2baseline lead-in
Long QT Syndrome (LQTS) 2Clinical Trials (1)
NCT07277582Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)
Phase 2/3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 6 clinical trials